FDA issues warning letter to Torrent Pharmaceuticals
Torrent Pharmaceuticals has received a warning letter from the FDA for violating cGMP regulations at its manufacturing facility in India.
List view / Grid view
Torrent Pharmaceuticals has received a warning letter from the FDA for violating cGMP regulations at its manufacturing facility in India.
Reyvow (lasmiditan), for the treatment of acute migraine, has received approval from the FDA following success in clinical trials.
The FDA has approved XARELTO® (rivaroxaban) to help prevent blood clots in acutely ill medical patients.
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
The FDA has announced its approval of Descovy, a PrEP method therapy, to reduce the risk of HIV-1 infection from sex.
The FDA recommends drug manufacturers to use LC-HRMS to test for NDMA in ranitidine products, as high temperatures generate the impurity.
The FDA has given a complete response letter to AstraZeneca for its PT010 treatment, regarding its New Drug Application.
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
The drug daratumumab has been approved for treatment of multiple myeloma, demonstrating increased efficacy when used in combination with other drugs.
The Jynneos live, non-replicating vaccination for smallpox and monkeypox has been approved by the FDA for high-risk patients.
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.